Several patients with severe combined immunodeficiency-X1 disease and adenosine deaminase deficiency have been cured by retroviral-mediated gene therapy. Despite the earlier success, the production of ...
Regulatory requirements stipulate that the production of any agents intended for use in human clinical trials must be performed under current Good Manufacturing Practices (cGMP). 1 Retroviral vector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback